KER-050 is a fusion protein commercialized by Keros Therapeutics, with a leading Phase II program in Thrombocytopenia. According to Globaldata, it is involved in 3 clinical trials, of which 1 was completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of KER-050’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for KER-050 is expected to reach an annual total of $210 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
KER-050 is under development for the treatment of cytopenias including anemia and thrombocytopenia in patients with myelodysplastic Syndrome (MDS) and myelofibrosis (MF). It is administered through subcutaneous route. The drug candidate is a protein which is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF-beta receptor, activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain.
It was also under development for the treatment of Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD)
Keros Therapeutics Overview
Keros Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. It is in the study of TGF-ß protein for the treatment of the development of therapeutics. The company’s product pipeline includes KER-050 for the treatment of low blood cell counts, cytopenias, including anemia and thrombocytopenia for patients with myelodysplastic syndrome (MDS) and myelofibrosis (MF); KER-047 for treating fibrodysplasia ossificans progressiva (FOP) and anemia from high hepcidin; KER-012 for treating disorders associated with bone loss, such as osteoporosis and also osteogenesis imperfecta and pulmonary arterial hypertension; and ActRll Variant targeting metabolic diseases. Keros Therapeutics is headquartered in Lexington, Massachusetts, the US.
The operating loss of the company was US$114.8 million in FY2022, compared to an operating loss of US$56.4 million in FY2021. The net loss of the company was US$104.7 million in FY2022, compared to a net loss of US$58.7 million in FY2021.
For a complete picture of KER-050’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.